Effect of omalizumab on patients with chronic urticaria

Spector, Sheldon L.; Tan, Ricardo

doi:10.1016/s1081-1206(10)60644-8

Cited by 157 publications

(83 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the patients with autoimmune urticaria had been under treatment for longer period before the symptoms were decreased. Similar results were also reported in previous study about the omalizumab effectivity in the treatment of chronic autoimmune urticaria [9,14]. on the 12 th dose, she had 48 bee-stings and developed only a slight local reaction which resolved spontaneously.…”

Section: Discussionsupporting

confidence: 90%

“…The use of omalizumab has been evaluated in several allergic conditions, including allergic rhinitis, asthma, Churg-Strauss syndrome, atopic eczema, urticaria, angioedema, latex allergy, and concurrently with allergy immunotherapy to try to blunt reactions [1][2][3][4][5][6][7][8][9][10]. While approved by US Food and Drug Administration for asthma, the other indications need to be studied further.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Yalçın¹

2012

J Aller Ther

View full text Add to dashboard Cite

Background: The primary use of omalizumab (trade name Xolair) is for patients with severe, persistent and allergic asthma. Our aim was to evaluate the therapeutic efficacy of omalizumab as a treatment modality in patients with different allergic conditions. Methods: There were eleven patients, whom followed-up with omalizumab therapy in the Immunology -Allergy Clinic, were evaluated by the clinical findings of nasal polyposis, anaphylaxis history, drug allergy, latex allergy, food allergy, autoimmune urticaria, allergic rhino-conjunctivitis, atopic dermatitis, angioedema and venom allergy. Results:The patients, who had severe persistent asthma for periods ranging from 3 to 8 years, were enrolled in the study. Omalizumab was chosen as a potential new systemic therapy for the patients due to the clinical indication. Clinical symptoms of the all patients with severe persistent asthma were decreased. And in addition, asthma control test and pulmonary function tests were improved up. A severe anaphylactic reaction is prevented in a patient with 48 bee stings. Conclusion:This clinical follow-up of omalizumab treated patients with severe persistent asthma and many different allergic conditions, suggests omalizumab is an effective therapy for asthma and different allergic conditions.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Yalçın¹

2012

J Aller Ther

View full text Add to dashboard Cite

show abstract

“…3,43 El tratamiento debe iniciarse con una dosis usual diaria del antihistamínico y que se incrementa gradualmente hasta lograr el control de la enfermedad o alcanzar 4 veces la dosis convencional. [44][45][46] Si no se logra el control, la adición de 150 a 300 mg [47][48][49] Existen otros medicamentos como la ciclosporina A, la cual se ha asociado con alta incidencia de efectos adversos, y el montelukast, que ha venido en desuso por el bajo nivel de la evidencia disponible. En casos refractarios es necesario utilizar esteroides sistémicos.…”

Section: Tratamientounclassified

Angioedema

Holguín-Gómez

Vásquez-Ochoa

Cardona

2016

RAM

View full text Add to dashboard Cite

Angioedema is defined as edema of the skin or mucosa, including the respiratory and the gastrointestinal mucosa, which is self-limiting, and in most cases is completely resolved in less than 72 hours. It occurs due to increased permeability of the mucosal and submucosal capillaries and postcapillary venules, with resulting plasma extravasation. There are different types of angioedema: histaminergic (which may be mediated by immunoglobulin E), hereditary, from acquired C1 inhibitor deficiency, from angiotensin converting enzyme inhibitor, bradykinin-mediated, and nonhistaminergic idiopathic angioedema. Treatment depends on the cause of angioedema, age, and the frequency and severity of manifestations. The main measures are avoiding external triggers or causes, giving antihistamines, steroids, or adrenaline for histaminergic angioedema; replacing the deficient protein or blocking the action of bradykinin in C1 inhibitor deficiency and angioedema from angiotensin converting enzyme inhibitor.

show abstract

“…Recent data also suggest reconsideration of the role of IgE antibodies in types of urticaria classified generally as non-allergic: this is true for cold-induced urticaria, which was already suspected as an IgE-mediated form because it could be reproduced by passive transport [6], and it has now been shown that anti-IgE treatment is able to prevent the clinical manifestations caused by exposure to cold [7]. Urticaria diagnosed as idiopathic may also be caused by IgE: three patients have been described recently with chronic urticaria resistant to any drug treatment who had total clearance following treatment with the anti-IgE omalizumab [8]. Similarly, three cases of refractory idiopathic angioedema were resolved by the same treatment [9], and this should lead to a reappraisal of the frequency of IgE-mediated urticaria/ angioedema.…”

Section: Urticaria/angioedemamentioning

confidence: 99%

Allergy and the skin

Incorvaia¹,

Frati

Verna

et al. 2008

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryAllergic skin disorders include urticaria, angioedema, contact dermatitis and atopic dermatitis, but the model fitting most closely the systemic concept of allergy is atopic dermatitis (AD), the pathogenesis of which is linked to a complex interaction between skin barrier dysfunction and environmental factors such as allergens and microbes. In particular, an important advance was the demonstration that the mutation of the skin barrier protein filaggrin is related strictly to allergen sensitization and to the development of asthma in subjects with AD. The altered skin barrier function, caused by several factors, results in the passage of allergens through the skin and to systemic responses. A pivotal role in such a response is exerted by Langerhans cells which, via their immunoglobulin E (IgE) receptor, capture the allergens and present them to T cells. When T helper type 2 (Th2) cells are activated, the production of a proinflammatory cytokines and chemokines pattern sustains the persistence of inflammation. Known AD-related cytokines are interleukin (IL)-5, IL-13 and tumour necrosis factor (TNF)-a, with emerging importance for IL-17, which seems to drive airway inflammation following cutaneous exposure to antigens, and IL-31, which is expressed primarily in skin-homing Th2 cells. Skin-homing is another crucial event in AD, mediated by the cutaneous lymphocyte-associated antigens (CLA) receptor, which characterizes T cell subpopulations with different roles in AD and asthma.

show abstract

Effect of omalizumab on patients with chronic urticaria

Cited by 157 publications

References 14 publications

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Omalizumab: Anti-IgE Therapy in Severe Allergic Conditions

Angioedema

Allergy and the skin

Contact Info

Product

Resources

About